Biohaven (NYSE:BHVN) Price Target Raised to $30.00

Biohaven (NYSE:BHVN) had its price objective boosted by TD Cowen from $15.00 to $30.00 in a research note released on Wednesday morning,Benzinga reports. TD Cowen currently has a buy rating on the stock.

A number of other research firms have also recently commented on BHVN. Leerink Partners reissued an “outperform” rating and issued a $15.00 price target on shares of Biohaven in a report on Tuesday, March 3rd. The Goldman Sachs Group raised shares of Biohaven to a “strong-buy” rating in a report on Friday, February 6th. Raymond James Financial restated a “strong-buy” rating on shares of Biohaven in a research report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Biohaven in a research note on Monday, December 29th. Finally, BTIG Research reiterated a “buy” rating and issued a $16.00 price target on shares of Biohaven in a report on Tuesday, November 18th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $24.93.

Biohaven Stock Performance

Shares of NYSE BHVN opened at $9.57 on Wednesday. The stock has a market cap of $1.01 billion, a PE ratio of -1.37 and a beta of 1.15. Biohaven has a 1 year low of $7.48 and a 1 year high of $31.18. The firm has a fifty day moving average price of $11.50 and a 200-day moving average price of $12.45. The company has a debt-to-equity ratio of 4.59, a current ratio of 3.18 and a quick ratio of 3.18.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, March 2nd. The company reported ($1.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.01. Equities analysts anticipate that Biohaven will post -8.9 earnings per share for the current fiscal year.

Institutional Trading of Biohaven

Several institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. lifted its stake in shares of Biohaven by 113.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after acquiring an additional 1,268 shares during the last quarter. PFS Partners LLC bought a new position in Biohaven in the 3rd quarter valued at $60,000. EverSource Wealth Advisors LLC increased its stake in Biohaven by 178.4% in the fourth quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company’s stock worth $46,000 after purchasing an additional 2,583 shares during the period. IFP Advisors Inc increased its stake in Biohaven by 55.4% in the fourth quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock worth $46,000 after purchasing an additional 1,450 shares during the period. Finally, Arax Advisory Partners boosted its stake in shares of Biohaven by 943.3% during the fourth quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock valued at $55,000 after purchasing an additional 4,443 shares during the period. Institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.